Mineralys Therapeutics logo
Mineralys Therapeutics
MLYS | NASDAQ
Chart Builder DCF Calculator
$14.53
-$0.80 (-5.22%)
At close: Nov 16, 2026, 4:00 PM ET
$14.29
-$0.24 (-1.65%)
After-hours: Nov 16, 2026, 7:30 PM ET

Mineralys Therapeutics Company Profile

Company profile explained

Company Profile

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Key Executives

Name Position
Jon Congleton President, Chief Executive Officer & Director
Adam Scott Levy Chief Financial Officer & Secretary
Jeffrey A. Munsie Chief Legal Officer
Brian Taylor Slingsby Founder & Executive Director
Danielle Mahoney Senior Vice President of Quality Assurance
Eric J. Warren Chief Commercial Officer
James J. Ferguson FACC Chief Medical Officer
Jessica Ibbitson Executive Vice President of Operations
Michael Tortorici Senior Vice President of Translational Medicine
Robert McKean Senior Vice President of CMC

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 20, 2026 4 Filing
Oct 20, 2026 3 Filing
Oct 20, 2026 4 Filing
Oct 20, 2026 3 Filing
Oct 19, 2026 8-K Current Report
Oct 02, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 22, 2026 4 Filing
Sep 17, 2026 4 Filing
View All SEC Filings ➞
Mineralys Therapeutics
Mineralys Therapeutics logo
Country United States
IPO Date Feb 10, 2023
Industry Biotechnology
Sector Healthcare
Employees 76
CEO Jon Congleton

Contact Details

150 N. Radnor Chester Rd. Radnor, Pennsylvania 19087 United States

Stock Details

Ticker Symbol MLYS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001933414
CUSIP Number 603170101
ISIN Number US6031701013
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.